Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 389 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Kenalog (Triamcinolone) Clear all
Completed Not applicable Interventional Results available

Study of Safety and Efficacy for the Eustachian Tube Balloon Catheter

NCT02087150
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
Acclarent Eustachian Tube Balloon Catheter (ETBC)
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
22 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
East Palo Alto, California • Washington D.C., District of Columbia • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 3, 2026, 6:55 PM EDT
Not listed Phase 2 Interventional

Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study

NCT01897259
View directory record Official record
Conditions
Tennis Elbow, Lateral Epicondylitis
Interventions
Placebo Injection, Physical Therapy, Corticosteroid Injections, Prolotherapy
Drug · Behavioral
Lead sponsor
Christine M. Kleinert Institute for Hand and Microsurgery
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 3, 2026, 6:55 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel

NCT00846690
View directory record Official record
Conditions
Dental Pain, Postoperative Pain
Interventions
benzocaine, TAC alternate gel
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
6655 Travis Suite 460, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Effect of Zilretta Injection

NCT04261049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone Acetonide Extended-Release Injectable Suspension
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 3, 2026, 6:55 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

NCT05862324
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
TAC01-CLDN18.2
Biological
Lead sponsor
Triumvira Immunologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Leukemia

NCT00019227
View directory record Official record
Conditions
Lymphoma, Radiation Toxicity
Interventions
pentetic acid calcium, yttrium Y 90 daclizumab
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

NCT01476839
View directory record Official record
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
basiliximab, carmustine, etoposide, cytarabine, melphalan, pharmacological study, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab
Biological · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

NCT04231318
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Cingal, Triamcinolone Hexacetonide (TH), Placebo
Drug
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

NCT01797432
View directory record Official record
Conditions
Alopecia Areata
Interventions
Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10), Restylane
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Conditioning, the Placebo Effect, and Psoriasis

NCT00005922
View directory record Official record
Conditions
Psoriasis
Interventions
Partial schedule of pharmacotherapeutic reinforcement, Dose control for Arm B, Standard pharmacotherapeutic protocol
Behavioral · Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
2
States / cities
Palo Alto, California • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids

NCT04710719
View directory record Official record
Conditions
Keloid, Keloid Scar Following Surgery
Interventions
Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil injection
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 3, 2026, 6:55 PM EDT
Completed No phase listed Observational

Do Knee Injections Offer Benefit With Knee Arthritis Pain

NCT04017949
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Corticosteroid injection
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

NCT02576938
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Baricitinib, Placebo, Triamcinolone (Optional)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

NCT00623766
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone, Corticosteroid: Fludrocortisone, Corticosteroid: Hydrocortisone, Corticosteroid: Meprednisone, Corticosteroid: Methylprednisolone, Corticosteroid: Prednisolone, Corticosteroid: Prednisone, Corticosteroid: Triamcinolone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
14
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 4 Interventional

Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain

NCT05161468
View directory record Official record
Conditions
Acromioclavicular Sprain
Interventions
Lidocaine injection, Corticosteroid Injection, Protein Rich Plasma(PRP) Injection
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 3, 2026, 6:55 PM EDT
Recruiting Phase 1 Interventional

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

NCT07734064
View directory record Official record
Conditions
Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Interventions
ASP2020
Drug
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Phoenix, Arizona • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 6:55 PM EDT
Not listed Early Phase 1 Interventional

Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome

NCT02031367
View directory record Official record
Conditions
Greater Trochanteric Pain Syndrome
Interventions
Triamcinolone Acetonide, Platelet Rich Plasma
Drug · Other
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses

NCT01736670
View directory record Official record
Conditions
Acute Steroid Responsive Dermatoses, Chronic Steroid Responsive Dermatoses
Interventions
Triamcinolone Acetonide spray, Triamcinolone acetonide cream, Alcohol spray
Drug
Lead sponsor
Patel, Rita Vikram, M.D.
Individual
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Suspended Phase 2 Interventional

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

NCT06680661
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept
Drug · Radiation · Biological
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 4 Interventional Results available

Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?

NCT03382925
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
cervical interlaminar with lidocaine, cervical interlaminar with normal saline, Lidocaine, Triamcinolone Acetonide, Normal saline
Procedure · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Intralesional Injections of Triamcinolone for Acne Vulgaris

NCT06170593
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Triamcinolone Injection
Drug
Lead sponsor
ACOM Labs
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 3, 2026, 6:55 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Biomarker Feedback Intervention

NCT07307326
View directory record Official record
Conditions
High Risk Drinking, College Student Drinking
Interventions
eCHECKUP TO GO (eCTG), eCHECKUPTOGO + brief personalized alcohol biomarker feedback intervention (eCTG + TAC)
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 23 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 3, 2026, 6:55 PM EDT